Herceptin blev undersøgt som adjuverende behandling i en multicenter, randomiseret undersøgelse (HERA), der sammenlignede 1- års Herceptin- behandling hver 3. uge versus observation hos patienter med tidlig HER2- positiv brystkræft efter operation, standard kemoterapi og strålebehandling (hvis indiceret).
In the adjuvant setting, Herceptin was investigated in a multicentre, randomised, trial (HERA) designed to compare one year of three-weekly Herceptin treatment versus observation in patients with HER2 positive early breast cancer following surgery, established chemotherapy and radiotherapy (if applicable).